As two leading entrepreneurs and investors in health technology companies, Dr. Maurice Ferre (co-founder and chairman) and Christopher Dewey (co-founder) identified a fundamental issue with skin cancer screening and lack of access to care for individuals with skin lesions of concern. This was particularly apparent in primary care where early detection of skin cancer is often hampered by limited consultation time and limited dermatology training, leading to a lack of confidence in diagnosing skin cancer.
They founded DermaSensor in 2009 and started collaborating with Dr. Irving Bigio, Professor of Biomedical Engineering at Boston University and one of the top spectroscopy researching in the world. Dr. Bigio is the original inventory and patent holder for Elastic Scattering Spectroscopy (ESS), a key component of the DermaSensor Device.
Since the invention of ESS in 1994, there have been over 1,000 ESS publications and over 50 publications on ESS clinics studies. DermaSensor began ints own skin-specific studies using this technology in 2011 and began its first study on the commercial prototype of the device in 2017.